The liver X receptor agonist AZ876 protects against pathological cardiac hypertrophy and fibrosis without lipogenic side effects

European Journal of Heart Failure

Volumn 17, Issue 3, 2015, Pages 273-282

  Cannon, Megan V ^a   Yu, Hongjuan ^a   Candido, Wellington M ^a   Dokter, Martin M ^a   Lindstedt, Eva Lotte ^b   Silljé, Herman H W ^a   Van Gilst, Wiek H ^a   De Boer, Rudolf A ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ASTRAZENECA R AND D   (Sweden)

Author keywords

Cardiac hypertrophy; Fibrosis; Heart failure; Liver X receptor; Nuclear receptor; Remodelling

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN II; AZ 876; CARDIOVASCULAR AGENT; LIVER X RECEPTOR AGONIST; LIVER X RECEPTOR ALPHA; PHENYLEPHRINE; SMAD2 PROTEIN; SMAD3 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; ACTA2 PROTEIN, MOUSE; ACTIN; ANILINE DERIVATIVE; LIPID; LIVER X RECEPTOR; ORPHAN NUCLEAR RECEPTOR; SMAD2 PROTEIN, MOUSE; SMAD3 PROTEIN, MOUSE; THIAZOLE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; BLOOD PRESSURE; CELL ISOLATION; CELLS BY BODY ANATOMY; COLLAGEN SYNTHESIS; CONTROLLED STUDY; FIBROBLAST; GENE EXPRESSION; GENE TARGETING; HEART FAILURE; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE HYPERTROPHY; HEART WEIGHT; IMMUNOCYTOCHEMISTRY; LIPID HOMEOSTASIS; LIVER WEIGHT; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TISSUE REGENERATION; TRIACYLGLYCEROL BLOOD LEVEL; UPREGULATION; AGONISTS; ANIMAL; BLOOD; C57BL MOUSE; CARDIOMEGALY; DISEASE MODEL; DRUG EFFECTS; FIBROSIS; GENE EXPRESSION REGULATION; GENETICS; LIPOGENESIS; METABOLISM; ORGAN SIZE; PATHOLOGY; PHYSIOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ACTINS; ANILINE COMPOUNDS; ANIMALS; CARDIOMEGALY; DISEASE MODELS, ANIMAL; FIBROSIS; GENE EXPRESSION REGULATION; LIPIDS; LIPOGENESIS; MICE; MICE, INBRED C57BL; ORGAN SIZE; ORPHAN NUCLEAR RECEPTORS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SMAD2 PROTEIN; SMAD3 PROTEIN; THIAZOLES; TRANSFORMING GROWTH FACTOR BETA; UP-REGULATION;

EID: 84924515362     PISSN: 13889842     EISSN: 18790844     Source Type: Journal    
DOI: 10.1002/ejhf.243     Document Type: Article

References (23)

1. Levy D, Garrison RJ, Savage DD, Kannel WB, Castelli WP,. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 1990; 322: 1561-1566.
2. Frey N, Olson EN,. Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 2003; 65: 45-79.
3. Peet DJ, Janowski BA, Mangelsdorf DJ,. The LXRs: a new class of oxysterol receptors. Curr Opin Genet Dev 1998; 8: 571-575.
4. Chen M, Beaven S, Tontonoz P,. Identification and characterization of two alternatively spliced transcript variants of human liver X receptor alpha. J Lipid Res 2005; 46: 2570-2579.
5. Calkin AC, Tontonoz P,. Liver X receptor signaling pathways and atherosclerosis. Arterioscler Thromb Vasc Biol 2010; 30: 1513-1518.
6. Zelcer N, Tontonoz P,. Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 2006; 116: 607-614.
7. Kuipers I, Li J, Vreeswijk-Baudoin I, Koster J, van der Harst P, Sillje HH, Kuipers F, van Veldhuisen DJ, van Gilst WH, de Boer RA,. Activation of liver X receptors with T0901317 attenuates cardiac hypertrophy in vivo. Eur J Heart Fail 2010; 12: 1042-1050.
8. Repa JJ, Liang G, Ou J, Bashmakov Y, Lobaccaro JM, Shimomura I, Shan B, Brown MS, Goldstein JL, Mangelsdorf DJ,. Regulation of mouse sterol regulatory element-binding protein-1c gene (SREBP-1c) by oxysterol receptors, LXRalpha and LXRbeta. Genes Dev 2000; 14: 2819-2830.
9. Morello F, de Boer RA, Steffensen KR, Gnecchi M, Chisholm JW, Boomsma F, Anderson LM, Lawn RM, Gustafsson JA, Lopez-Ilasaca M, Pratt RE, Dzau VJ,. Liver X receptors alpha and beta regulate renin expression in vivo. J Clin Invest 2005; 115: 1913-1922.
10. Kuipers I, van der Harst P, Kuipers F, van Genne L, Goris M, Lehtonen JY, van Veldhuisen DJ, van Gilst WH, de Boer RA,. Activation of liver X receptor-alpha reduces activation of the renal and cardiac renin-angiotensin-aldosterone system. Lab Invest 2010; 90: 630-636.
11. Leik CE, Carson NL, Hennan JK, Basso MD, Liu QY, Crandall DL, Nambi P,. GW3965, a synthetic liver X receptor (LXR) agonist, reduces angiotensin II-mediated pressor responses in Sprague-Dawley rats. Br J Pharmacol 2007; 151: 450-456.
12. Loren J, Huang Z, Laffitte BA, Molteni V,. Liver X receptor modulators: a review of recently patented compounds (2009-2012). Expert Opin Ther Pat 2013; 23: 1317-1335.
13. van der Hoorn J, Linden D, Lindahl U, Bekkers M, Voskuilen M, Nilsson R, Oscarsson J, Lindstedt E, Princen H,. Low dose of the liver X receptor agonist, AZ876, reduces atherosclerosis in APOE∗3Leiden mice without affecting liver or plasma triglyceride levels. Br J Pharmacol 2011; 162: 1553-1563.
14. Tontonoz P, Mangelsdorf DJ,. Liver X receptor signaling pathways in cardiovascular disease. Mol Endocrinol 2003; 17: 985-993.
15. Wu S, Yin R, Ernest R, Li Y, Zhelyabovska O, Luo J, Yang Y, Yang Q,. Liver X receptors are negative regulators of cardiac hypertrophy via suppressing NF-kappaB signalling. Cardiovasc Res 2009; 84: 119-126.
16. Dobaczewski M, Chen W, Frangogiannis NG,. Transforming growth factor (TGF)-beta signaling in cardiac remodeling. J Mol Cell Cardiol 2011; 51: 600-606.
17. Antonson P, Jakobsson T, Almlof T, Guldevall K, Steffensen KR, Gustafsson JA,. RAP250 is a coactivator in the transforming growth factor beta signaling pathway that interacts with Smad2 and Smad3. J Biol Chem 2008; 283: 8995-9001.
18. Tachibana H, Ogawa D, Matsushita Y, Bruemmer D, Wada J, Teshigawara S, Eguchi J, Sato-Horiguchi C, Uchida HA, Shikata K, Makino H,. Activation of liver X receptor inhibits osteopontin and ameliorates diabetic nephropathy. J Am Soc Nephrol 2012; 23: 1835-1846.
19. Shi Y, Xu X, Tan Y, Mao S, Fang S, Gu W,. A liver-X-receptor ligand, T0901317, attenuates IgE production and airway remodeling in chronic asthma model of mice. PLoS One 2014; 9: e92668.
20. Pathak M, Sarkar S, Vellaichamy E, Sen S,. Role of myocytes in myocardial collagen production. Hypertension 2001; 37: 833-840.
21. Koitabashi N, Arai M, Kogure S, Niwano K, Watanabe A, Aoki Y, Maeno T, Nishida T, Kubota S, Takigawa M, Kurabayashi M,. Increased connective tissue growth factor relative to brain natriuretic peptide as a determinant of myocardial fibrosis. Hypertension 2007; 49: 1120-1127.
22. Panse KD, Felkin LE, Lopez-Olaneta MM, Gomez-Salinero J, Villalba M, Munoz L, Nakamura K, Shimano M, Walsh K, Barton PJ, Rosenthal N, Lara-Pezzi E,. Follistatin-like 3 mediates paracrine fibroblast activation by cardiomyocytes. J Cardiovasc Transl Res 2012; 5: 814-826.
23. Brouwers FP, de Boer RA, van der Harst P, Voors AA, Gansevoort RT, Bakker SJ, Hillege HL, van Veldhuisen DJ, van Gilst WH,. Incidence and epidemiology of new onset heart failure with preserved vs. reduced ejection fraction in a community-based cohort: 11-year follow-up of PREVEND. Eur Heart J 2013; 34: 1424-1431.